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A B S T R A C T
Dementia with Lewy bodies (DLB) is characterized by alpha-synuclein protein deposition with variable degree of
concurrent Alzheimer's pathology. Neuroinﬂammation is also increasingly recognized as a signiﬁcant con-
tributor to degeneration. We aimed to examine the relationship between microglial activation as measured with
[11C]-PK11195 brain PET, MR diﬀusion tensor imaging (DTI) and grey matter atrophy in DLB. Nineteen clini-
cally probable DLB and 20 similarly aged controls underwent 3T structural MRI (T1-weighted) and diﬀusion-
weighted imaging. Eighteen DLB subjects also underwent [11C]-PK11195 PET imaging and 15 had [11C]-
Pittsburgh compound B amyloid PET, resulting in 9/15 being amyloid-positive. We used Computational
Anatomy Toolbox (CAT12) for volume-based morphometry (VBM) and Tract-Based Spatial Statistics (TBSS) for
DTI to assess group comparisons between DLB and controls and to identify associations of [11C]-PK11195
binding with grey/white matter changes and cognitive score in DLB patients. VBM analyses showed that DLB had
extensive reduction of grey matter volume in superior frontal, temporal, parietal and occipital cortices (family-
wise error (FWE)-corrected p< 0.05). TBSS showed widespread changes in DLB for all DTI parameters (reduced
fractional anisotropy, increased diﬀusivity), involving the corpus callosum, corona radiata and superior long-
itudinal fasciculus (FWE-corrected p< 0.05). Higher [11C]-PK11195 binding in parietal cortices correlated with
widespread lower mean and radial diﬀusivity in DLB patients (FWE-corrected p< 0.05). Furthermore, preserved
cognition in DLB (higher Addenbrookes Cognitive Evaluation revised score) also correlated with higher [11C]-
PK11195 binding in frontal, temporal, and occipital lobes. However, microglial activation was not signiﬁcantly
associated with grey matter changes. Our study suggests that increased microglial activation is associated with a
relative preservation of white matter and cognition in DLB, positioning neuroinﬂammation as a potential early
marker of DLB etio-pathogenesis.
1. Introduction
Dementia with Lewy bodies (DLB) is the second-leading degen-
erative dementia in older people (Vann Jones and O'Brien, 2014). It is
characterized by alpha-synuclein protein deposition in the form of
intra-neuronal Lewy bodies as well as Lewy neurites, with a variable
degree of concurrent Alzheimer's disease (AD) pathology
(Spillantini et al., 1997; Gomperts, 2016). Neuroinﬂammation and,
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more speciﬁcally microglial activation, is increasingly recognized as a
key etio-pathogenic mechanism in DLB which can be assessed in vivo
via diﬀerent PET tracers including [11C]-PK11195 (PK11195)
(Turkheimer et al., 2007). In DLB, increased microglial activation as
assessed via PK11195 has been observed in the striatum, substantia
nigra, and several cortical regions (Iannaccone et al., 2013;
Surendranathan et al., 2018). Intriguingly, we have recently found that
patients with cognitively mild forms of DLB have higher PK11195
binding than those with moderate cognitive impairment in the caudate,
thalamus as well as frontal, temporal, and parietal cortices
(Surendranathan et al., 2018). Other studies have also shown that mi-
croglial activation is an initial event in AD, mirroring the neuropatho-
logical changes primarily involving temporo-parietal regions
(Hamelin et al., 2016; Passamonti et al., 2018). In addition, long-
itudinal data regarding neuroinﬂammation activation in mild cognitive
impairment (MCI) have shown a decreased microglial activation at 14-
month follow-up (Fan et al., 2017). Increased microglial activation in
MCI was also associated with a preserved hippocampal volume
(Femminella et al., 2019). Together, these results suggest that neu-
roinﬂammation represents an early event in the neurodegeneration
process and could be a potential therapeutic target in dementia. In fact,
unlike molecules targeting protein accumulation which are currently at
an experimental stage, anti-inﬂammatory drugs are readily available
and could be employed more quickly into clinical drug trials. An im-
portant prerequisite for such an endeavour is a better understanding of
the temporal ordering and clinical relevance of protein accumulation,
neuroinﬂammation, and structural brain changes.
White matter microstructure has received growing research atten-
tion as a sensitive marker for early structural brain changes. Diﬀusion-
tensor imaging (DTI) is sensitive to Brownian motion of water mole-
cules, from which microstructural features and associated pathological
processes can be inferred from the relative coherence or magnitude of
diﬀusion along the major axis of a white matter bundle. Fractional
anisotropy (FA) is a scalar index (range: 0–1) reﬂecting the directional
coherence of water diﬀusion. Mean diﬀusivity (MD) represents the
overall magnitude of diﬀusion and is widely thought to be sensitive to
cell loss, cellularity, edema and necrosis (Pierpaoli and Basser, 1996;
Alexander et al., 2007). A less commonly studied marker is radial dif-
fusivity (RD), which has been linked to demyelination as well as pa-
thological changes in axonal density (Klawiter et al., 2011). The lit-
erature has consistently shown reduced FA and increased MD/RD in
DLB, especially in the absence of the marked brain atrophy that is ty-
pically seen in late-onset AD (Kantarci et al., 2010; Watson et al., 2012;
Nedelska et al., 2015). Several pathological mechanisms for such white
matter changes have been described in dementia, including ischaemia,
demyelination and amyoid angiopathy (Gold et al., 2012; Chao et al.,
2013; Kantarci et al., 2017). In addition to white matter changes sec-
ondary to grey matter atrophy and amyloid burden (i.e. Wallerian de-
generation) (Amlien and Fjell, 2014), several other contributors such as
vascular damage and tau deposition can contribute to primary white
matter changes, especially in late-myelinated projection ﬁbers
(Bartzokis et al., 2007).
In the present study, we aimed to characterize the relationship be-
tween microglial activation as measured with PK11195 PET and DTI
impairment in a cross-sectional group of subjects with probable DLB,
most of which having amyloid status additionally conﬁrmed through
PiB PET imaging (Surendranathan et al., 2018). We recently observed
that DLB subjects with a milder cognitive impairment had widespread
higher cortical PK11195 binding. In addition, recent studies in MCI
suggest an early peak of microglial activation in MCI. Therefore, we
hypothesized that higher microglial activation would correlate with a
relative preservation of white matter microstructural integrity.
2. Methods
2.1. Participants
The present work is part of the Neuroimaging of Inﬂammation in
MemoRy and Other Disorders (NIMROD) study (Bevan-Jones et al.,
2017). All participants were aged over 50 years and had suﬃcient
proﬁciency in English for cognitive testing. We included 19 participants
with probable DLB according to both 2005 and 2017 consensus criteria
(McKeith et al., 2005; McKeith et al., 2017) as described in
(Surendranathan et al., 2018). In addition, subjects had at least two
years clinical follow-up to conﬁrm clinical progression and no change of
diagnosis. We also recruited 20 similarly aged healthy controls, with
MMSE scores greater than 26, absence of regular memory complaints,
and no unstable or signiﬁcant medical illnesses. A detailed clinical and
neuropsychological assessment was performed (Bevan-Jones et al.,
2017). This included Addenbrooke's Cognitive Examination Revised
test (ACE-R) which is a 100-point test incorporating ﬁve key cognitive
domains in dementia disorders (orientation/attention, memory, verbal
ﬂuency, language, and visuo-spatial) (Mioshi et al., 2006).
Patients were identiﬁed from the Memory clinic at the Cambridge
University Hospitals NHS Trust, other local memory clinics, and from
the Dementias and Neurodegenerative Diseases Research Network
(DeNDRoN) volunteer registers. Healthy controls were recruited via
DeNDRoN as well as from spouses and partners of participants.
Informed written consent was obtained in accordance with the
Declaration of Helsinki. The study received a favourable opinion from
the East of England Ethics Committee (Cambridge Central Research,
Ref. 13/EE/0104).
2.2. MRI and PET acquisition
Nineteen subjects with probable DLB underwent multi-modal 3T
MPRAGE and diﬀusion-weighted imaging (DWI) as described in detail
below. 18/19 DLB participants also had [11C]-PK11195 PET imaging on
a GE Advance or GE Discovery 690 PET/CT scanner. To ensure accurate
correlations between MRI and PET imaging, we aimed at keeping scan
interval between MRI and PET within 3 months (mean interval 2.4
months). Each [11C]-PK11195 PET image series was aligned across the
time frames with SPM12 to ameliorate the impact of head motion
during data acquisition. The realigned dynamic PET images were co-
registered to the corresponding T1-weighted MPRAGE images, as were
regions of interest (ROIs) from the Hammers atlas (Hammers et al.,
2003) using ANTs for the inverse spatial normalisation from MNI to
MPRAGE space. Prior to kinetic modelling, regional time-activity
curves (TACs) were corrected for CSF contamination through division
by the mean ROI fraction of grey plus white matter, using SPM12 tissue
probability maps smoothed to PET spatial resolution. Binding in each
ROI was quantiﬁed using non-displaceable binding potential (BPND)
determined with reference tissue TAC estimation from supervised
cluster analysis and a simpliﬁed reference tissue model incorporating
vascular binding correction (Yaqub et al., 2012). In fact, the partial
volume correction method applied to the dynamic PK11195 images to
address diﬀerential atrophy is the two-compartment (brain, CSF)
Meltzer method, which has been shown to be more robust to registra-
tion and segmentation errors than the three-compartment version.
Furthermore, this method is well suited to the production of the
PK11195 reference time activity curve from supervised cluster analysis
(SCA), whereas the geometric transfer matrix (GTM) approach cannot
be applied given that SCA is a voxel-wise technique.
For each subject, we derived a composite PK11195 BPND (global) by
averaging the PK11195 binding across each cortical ROI and hemi-
sphere from the Hammers atlas, as well as lobar PK11195 BPND (i.e.,
frontal, temporal, parietal, occipital). In addition, 15 DLB subjects un-
derwent [11C]-PiB PET imaging to quantify the density of ﬁbrillar Aβ
deposits for classiﬁcation of Aβ status (positive when PiB cortical
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standardized uptake value ratio (SUVR) > 1.5) (Jagust et al., 2010).
[11C]-PiB data were quantiﬁed using SUVR with the superior cerebellar
grey matter as the reference region. The [11C]-PiB SUVR data were
subjected to the GTM technique using Freesurfer's PETsurfer
(Greve et al., 2014), including partial volume correction.
2.3. Diﬀusion-weighted imaging
The DWI acquisition protocol was as follows: 63 slices of 2.0 mm
thickness, TE = 106 ms, TR = 11,700 ms, SENSE = 2, ﬁeld of
view = 192 × 192 mm2. The data were preprocessed with the FSL 5.0
software package (http://www.fmrib.ox.ac.uk/fsl). This included re-
gistration of all diﬀusion-weighted images to the b = 0 (i.e. no diﬀu-
sion) volume using the FSL Diﬀusion Toolbox (FDT), followed by brain
masks creation with Brain Extraction Tool (BET), head movement and
eddy currents correction. We then used DTIﬁt to independently ﬁt the
diﬀusion tensor for each voxel, resulting in the derivation of FA, MD
and RD.
2.4. Volume-based morphometry
In addition, volume-based morphometry (VBM) analyses were per-
formed using high-resolution T1-weighted MPRAGE images, including
group comparisons between DLB and Controls, as well as voxel-wise
correlational grey matter maps of global/lobar PK11195 binding, in
order to assess whether grey matter atrophy/preservation was sig-
niﬁcantly associated with increased microglial activation.
Computational Anatomy Toolbox 12 (CAT12) was used to create 8mm-
smoothed VBM maps, after using the standard CAT12 pipeline pre-
viously described in Nicastro et al. (2019).
2.5. Statistical analyses
Tract-based spatial statistics (TBSS) was implemented in the FSL
workspace to align each subject's FA image to a pre-identiﬁed target FA
image (FMRIB_58) (Smith et al., 2004). All aligned FA images were then
aﬃne-registered into the Montreal Neurological Institute (MNI)
MNI152 template. The mean FA and skeleton were created for all
subjects and each FA image was then projected onto the skeleton. The
skeleton was thresholded at FA value of 0.2 to include white matter
tracts that are common across all subjects, as well as to further exclude
voxels that may contain grey matter or CSF. The aligned DTI parameter
map of each subject was then projected onto the mean skeleton. In
addition, other DTI parameters were aligned by applying the original
FA non-linear spatial transformations to the corresponding datasets and
projecting them onto the mean FA skeleton. Subsequently, the rando-
mise function in FSL was implemented to identify group diﬀerences in
DTI parameters between DLB and age-matched healthy controls, using a
two-sample t-test while controlling for age and sex. VBM group com-
parisons between DLB and Controls were performed using the TFCE
toolbox with non-parametric randomisation (n = 5000 permutations)
and family-wise error (FWE)-corrected two-tailed p < 0.05 threshold,
with age, sex and total intracranial volume as covariates.
Voxel-wise correlation between DTI and PK11195 was performed
with TBSS using age, sex, scan interval between MRI and PET imaging,
as well as ACER score as nuisance covariates in the design matrix.
Global and lobar PK11195 uptake was treated as the independent
variable for each DTI parameter across the white matter skeleton. The
statistical signiﬁcance from these tests was determined using non-
parametric permutation testing (n = 5000 permutations) and adjusted
for multiple comparisons FWE correction and using two-tailed p< 0.05
signiﬁcance threshold (Smith and Nichols, 2009), thus obviating the
need to set an arbitrary cluster threshold. Anatomical deﬁnitions of
signiﬁcant TBSS clusters were performed visually and facilitated using
the John Hopkins – ICBM white matter atlas, available as part of the
FSL package. Finally, the statistical maps were dilated with tbss_ﬁll
function for visualisation purposes. Similarly, voxelwise VBM correla-
tional maps with global/lobar PK11195 were obtained for DLB subjects,
using the same covariates as for DTI correlations (in addition to total
intracranial volume). False-discovery rate (FDR) p< 0.05 was used as a
signiﬁcance threshold.
3. Results
3.1. Demographics
The demographics and clinical characteristics are reported in
Table 1. Both groups were comparable in terms of age, sex and years of
education. As expected, MMSE and ACER scores were signiﬁcantly
lower in the DLB group relative to the healthy controls (p < 0.001,
Mann-Whitney U test).
3.2. Group comparisons of DTI/VBM parameters
Voxel-based TBSS analyses revealed that the DLB group relative to
controls had signiﬁcant white matter changes in the body and splenium
of corpus callosum. These ﬁndings were consistently observed for all
three DTI metrics (decreased FA, increased MD and RD). In addition, we
observed reduced FA and increased RD for DLB in right anterior and
posterior corona radiata, left cingulate gyrus, and right superior long-
itudinal fasciculus (Fig. 1) (all FWE-corrected p < 0.05).
Subgroup analyses of DLB subjects according to their PiB status
revealed a more extensive impairment in the PiB+ DLB (n = 9) com-
pared to controls, with virtually every subcortical tract being impaired.
In contrast, there was no signiﬁcant DTI changes in the PiB- DLB sub-
group (n = 6) compared to controls. DTI group comparisons between
PiB+ (n= 9) and PiB- DLB (n= 6) did not show any signiﬁcant cluster
(all FWE-corrected p > 0.17).
VBM group comparisons showed that, in comparison to Controls,
DLB subjects had lower grey matter volume in regions including bi-
lateral superior and middle frontal, middle and posterior temporal,
inferior parietal and lateral occipital cortices (FWE-corrected p < 0.05,
Fig. 2).
3.3. PK11195 binding in DLB
As previously shown with the same DLB group
(Surendranathan et al., 2018), PK11195 PET comparisons with a si-
milarly-aged control group showed that DLB subjects had higher
PK11195 binding in the fusiform gyrus and putamen (p < 0.01, Mann-
Whitney U test). Using a median-split approach to dichotomise DLB
subjects into a mild cognitive impairment subgroup (ACER score >65/
100) and a moderate-severe cognitive impairment subgroup (ACER
score ≤65/100) revealed that the “mild” DLB group had higher
PK11195 binding than Controls in the inferior and medial temporal
gyrus, fusiform gyrus, putamen, inferior frontal gyrus and cuneus.
Conversely, there was no signiﬁcant diﬀerence between the moderate-
severe DLB subgroup and Controls, except for a higher PK11195 in the
caudate nucleus for the Control group (details available in
Table 1
Clinical characteristics of study sample.
DLB (n = 19) HC (n = 20) p-value
Age (years) 73.5 ± 6.1 (62–82) 71.0 ± 6.9 (56–81) 0.23 *
Male/Female Ratio 3.8 (15/4) 1 (10/10) 0.06 $
Education (years) 12.0 ± 2.3 (8–17) 13.4 ± 2.8 (9–19) 0.10 *
MMSE 22.5 ± 4.3 (15–28) 28.8 ± 1.2 (26–30) <0.0001 #
ACER 66.8 ± 11.9 (45–87) 90.9 ± 6.6 (75–100) <0.0001 #
Abbreviations: M/F = Male/Female, MMSE = Mini-Mental State Examination,
ACER = Addenbrooke's Cognitive Evaluation Revised, * = t-test, # = Mann-
Whitney, $ = Chi-Square test.
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(Surendranathan et al., 2018)). In addition, we observed that DLB
subjects had lower BPND in the parietal lobe (0.03 ± 0.06) compared
to the frontal (0.10 ± 0.08, p = 0.008) and occipital lobes
(0.11 ± 0.08, p = 0.002, Mann-Whitney U test).
Higher ACER score was signiﬁcantly correlated with higher
PK11195 binding in frontal (Spearman ρ = 0.52, p = 0.03, 95% CI
0.137 – 0.91), temporal (ρ= 0.50, p= 0.03, 95% CI 0.128–0.878) and
occipital lobe (ρ = 0.55, p = 0.02, 95% CI 0.209–0.898), with a trend
for global PK (ρ = 0.46, p = 0.052, 95% CI 0.094–0.834) but not with
parietal PK binding (ρ = 0.26, p = 0.23, 95% CI −0.185–0.741).
3.4. Voxel-wise association of imaging data
TBSS analyses revealed that for DLB subjects, higher parietal
PK11195 uptake was associated with a relative preservation of white
matter (i.e., lower MD and RD) in bilateral corona radiata, posterior
thalamic radiations, sagittal stratum, left superior longitudinal fasci-
culus, as well as frontal and parietooccipital white matter tracts (two-
tailed FWE p < 0.05) (Fig. 3). We did not ﬁnd signiﬁcant associations
between PK11195 and FA (p = 0.05), nor were there any signiﬁcant
correlations in the opposite contrasts for MD and RD.
PK11195 – DTI correlation analyses did not reach a signiﬁcant
threshold regarding PK11195 at the global (all p > 0.13), frontal (all
p> 0.13), temporal (all p> 0.08) and occipital level (all p> 0.13) (all
voxelwise FWE-corrected).
Regarding voxelwise correlations between DTI and lobar/global
amyloid load in the subset of DLB subjects with available PiB PET
(n = 15), these analyses did not reach statistical signiﬁcance (all FWE-
corrected p > 0.3).
In addition, no signiﬁcant correlation was observed in the DLB
group between VBM maps and global/lobar (increased or decreased)
PK11195 binding (all FDR-corrected p > 0.3).
4. Discussion
In the present study, we found evidence of relative DTI preservation
for DLB in relation to increased microglial activation as measured with
PK11195. This is consistent with our previous data showing that neu-
roinﬂammation in fronto-temporo-parietal cortices was more promi-
nent in DLB subjects with milder cognitive impairment, suggesting that
central inﬂammation plays a pivotal role in the early stages of the
disease (Surendranathan et al., 2018). No such correlation (either ne-
gative or positive) was observed between grey matter volume and
PK11195 binding - microglial activation does not decrease in relation to
Fig. 1. DTI group comparisons showing increased radial diﬀusivity (red) in DLB subjects compared to healthy control group (FWE p < 0.05). (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. VBM group comparisons showing reduced grey matter
volume (blue-green) for DLB subjects in bilateral superior
frontal, medial, lateral and posterior temporal, parietal and
lateral occipital cortices (FWE p < 0.05). (For interpretation of
the references to color in this ﬁgure legend, the reader is re-
ferred to the web version of this article.)
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grey matter atrophy and conversely, increased neuroinﬂammation is
not directly related to preserved grey matter volume.
Extensive grey and white matter abnormalities were observed in
DLB compared to healthy controls. Patients exhibited grey matter
atrophy in extensive frontal, temporal, parietal and occipital cortices
(Fig. 2), while DTI changes were observed in the corpus callosum,
corona radiata, superior longitudinal fasciculus and left cingulum
(Fig. 1), which is in keeping with previous studies (Firbank et al., 2007;
Kantarci et al., 2010; Watson et al., 2012; Delli Pizzi et al., 2015;
Firbank et al., 2016). Subgroup analyses according to the PiB status
showed that PiB+ DLB subjects had more extensive DTI changes, en-
compassing virtually every tract of the white matter skeleton. Most
likely due to a small sample size, we did not ﬁnd any signiﬁcant DTI
diﬀerence between PiB+ and PiB- DLB subjects. Interestingly, previous
studies showed altered DTI metrics in parietal and occipital white
matter tracts in DLB, irrespective of the amyloid load (Nedelska et al.,
2015).
Studies in AD report that white matter changes can occur secon-
darily to grey matter damage (Wallerian degeneration) (Amlien and
Fjell, 2014) following amyloid accumulation in soluble oligomers or
plaques. Cell death will lead to axonal disruption in white matter tracts
connecting the aﬀected cortical areas. However, there is also evidence
of primary white matter changes, which can be attributed to vascular
damage or hyperphosphorylated tau deposition, resulting in the for-
mation of paired helical ﬁlaments primarily aﬀecting the axons. The
retrogenesis hypothesis stipulates that primary white matter degen-
eration follows an inverse path than what is observed during myelo-
genesis, i.e., early-myelinated large-diameter ﬁbres are aﬀected last,
while late-myelinated projecting ﬁbres shown early disruption
(Bartzokis et al., 2007). Longitudinal DTI studies accounting for tau
deposition and vascular burden are warranted to disentangle primary
and secondary white matter changes in dementias.
In the present study, we also observed that higher parietal PK11195
binding was correlated with relative DTI preservation (i.e., lower dif-
fusivity) in the corona radiata and superior longitudinal fasciculus, i.e.,
the same tracts which are impaired in DLB compared to controls
(Fig. 3). Thus, the spatial congruence of both statistical maps –
subjected to the same rigorous statistical thresholds – confer support for
the view that white matter deﬁcits may be a secondary event to various
processes such as protein deposition and possibly neuroinﬂammation.
In addition, we observed a broad overlap between the ﬁndings of MD
and RD parameters regarding the correlation of DTI values and
PK11195 binding. Higher MD values indicate increased diﬀusion, sug-
gesting tissue breakdown and increased brain water content. Con-
versely, higher RD is considered as a more speciﬁc marker of myelin
damage (Pierpaoli and Basser, 1996; Song et al., 2005). As previously
reported, MD (and RD) appears as a more sensitive proxy of white
matter damage than FA in patients with DLB (Watson et al., 2012;
O'Donovan et al., 2014; Delli Pizzi et al., 2015).
Whereas lower MD and RD DTI values are related to higher parietal
PK11195, the analyses did not reach statistical signiﬁcance for
PK11195 binding in the other lobes, although we observed a trend for
temporal lobe (p > 0.08). Considering this is a cross-sectional study,
one could only speculate about the reasons why parietal PK11195 is
more closely related to DTI preservation than the other brain regions.
We can hypothesize that the dynamic changes in parietal PK11195 are
temporally more related to DTI changes, possibly as parietal PK11195 is
decreasing simultaneously with appearing white matter changes. In
fact, we observed that PK11195 binding in the parietal lobe was sig-
niﬁcantly lower compared to the frontal and occipital lobes.
Studies using TSPO PET ligands in degenerative conditions have
reported conﬂicting results about the trajectory of microglial activation.
One hypothesis suggests that neuroinﬂammation is more prominent at
earlier stages of degenerative conditions. In fact, Femminella et al.
(Femminella et al., 2019) showed that increased microglial activation
as measured with [11C]-PBR28 PET in MCI subjects was associated with
higher grey matter and hippocampal volume. Similarly, Hamelin et al.
(Hamelin et al., 2016) observed that higher TSPO binding (using 18F-
DPA-714) was positively correlated with higher MMSE and larger grey
matter volume in AD. Moreover, a recent study in a transgenic amyloid
mouse model (Blume et al., 2018) using longitudinal TSPO and amyloid
PET showed that microglial response declined relative to increasing
amyloidosis, possibly due to a saturation eﬀect. Interestingly, while our
results suggest that increased TSPO binding is directly related to lower
Fig. 3. TBSS correlation analyses showing decreased radial diﬀusivity (blue) correlated with higher parietal 11C-PK11195 binding in DLB subjects (FWE p < 0.05).
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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diﬀusivity, no such relationship could be established between PK11195
binding and grey matter volume. These ﬁndings are crucial as they
suggest that decreased microglial activation with progressive impair-
ment of DTI metrics and cognition is not secondary to grey matter
atrophy.
As discussed in a recent meta-analysis (Bradburn et al., 2019), the
predominant hypothesis posits that neuroinﬂammation peaks early in
MCI, followed by a second peak when MCI convert to AD, possibly
reﬂecting the complex relationship between microglial activation and
protein deposition internalized by glia (Fan et al., 2017). Therefore, our
observations in DLB suggest a diﬀerent pattern of microglial activation
in dementias compared to primary inﬂammatory conditions, where
TSPO ligand changes are more related to clinical relapses, as this is the
case in multiple sclerosis (Rissanen et al., 2018).
Regarding the relationship between amyloid load and PK11195
binding, we did not observe any signiﬁcant correlation between lobar
or global PiB SUVR and PK11195 BPND, suggesting that amyloid load is
not a major driver of neuroinﬂammation in DLB, or that any such re-
lationship is weak. These ﬁndings are in contrast with those observed in
AD (Fan et al., 2015).
The present study is not without limitations. First, our results have
been obtained on a relatively modest sample of subjects with DLB, so
this would require conﬁrmation in larger samples, especially since we
found a trend between higher microglial activation in the temporal lobe
and DTI preservation. In addition, while subgroup analyses based on
the amyloid status would certainly be of interest, our small sample
impeded us to assess whether concurrent AD pathology might play an
additional role in the complex relationship between neuroinﬂammation
and white matter tracts integrity. Second, the present study was based
on data obtained with a cross-sectional design. Therefore, longitudinal
data is required to fully assess the spatial and temporal interplay be-
tween white matter integrity and neuroinﬂammation in DLB. If on the
one hand, white matter degeneration can be considered as an early
structural marker in neurodegenerative disorders, it can be equally
possible that neuroinﬂammation precipitates white matter damage and
thus represents a relatively “upstream” event in the cascade leading to
cellular loss in DLB. In addition, we must acknowledge that there was a
larger male distribution in the DLB group (15/19 versus 10/20 for
Controls, p = 0.06) and although we used sex as a covariate for our
correlational analyses, we cannot exclude that sex might play a role in
DTI integrity. In fact, Kumar et al. showed that females had a lower
myelin and ﬁber integrity in limbic and cerebellar regions, while males
had lower values in frontal and temporal areas (Kumar et al., 2013).
Additionally, we are not aware of a diﬀerent microglial activation based
on sex.
The use of PK11195 targeting translocator protein (TSPO) cannot
fully represent the extent of central inﬂammation which is determined
by several other factors over and above microglial activation. In fact,
other targets such as astrocyte activation should be assessed as they also
may play a role in the development of neurodegeneration
(Stefaniak and O'Brien, 2016). In addition, PK11195, as a ﬁrst gen-
eration TSPO ligand, has shown lower sensitivity compared to second
generation tracers. However, PK11195 has the advantage of not being
aﬀected by the genetic polymorphism (notably rs6971 single nucleo-
tide) altering the binding of second-generation ligands (Owen et al.,
2012).
Finally, although TBSS is a widely used DTI analysis software, in-
herent limitations must be acknowledged, e.g. the fact that the pro-
jection of the common white matter skeleton is based on FA maps ra-
ther than tensor-based. In addition, the registration target was
performed on the FMRIB58 skeleton (as recommended by FSL) rather
than on a study-speciﬁc skeleton (Bach et al., 2014). In addition, we
must acknowledge that the tensor model used in the present study does
not address the issue of crossing ﬁbres, which can represent 70% of the
conﬁguration of white matter ﬁbres. More sophisticated models, in-
cluding diﬀusion and ﬁbre orientation density stand as a more eﬀective
way to describe the complex organisation of white matter tracts
(Dell'Acqua and Tournier, 2019).
In conclusion, we present novel evidence of the in vivo association
between lower DTI diﬀusivity and increased microglial activation in
DLB. Future longitudinal studies are required to determine whether the
early presence of neuroinﬂammation in DLB recedes and mediates the
structural brain abnormalities that we have observed.
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